-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, the Beijing Municipal Medical Insurance Bureau and other two departments jointly issued a notice to adjust the medical insurance catalog
.
The notice shows that from January 1, 2022, 74 new drugs will be added to the list of Beijing’s medical insurance drugs, a drop of more than half.
Beijing’s urban employees, urban and rural residents and other insured persons can enjoy reduced prices
.
It is reported that the notice is based on the adjustment of the national 2021 version of the drug catalog, the Beijing medical insurance drug catalog has been adjusted in and out, the scope and category of reimbursement for some drugs have been adjusted, and the reimbursement policy for medicines such as special diseases in outpatient clinics of this city has been adjusted.
Perfect
.
The 74 new drugs have an average decrease of 61.
71%, covering tumors, chronic diseases, anti-infection, rare diseases and other fields.
They are the nationally negotiated drugs for 2021.
The adjustment in Beijing is to implement the national 2021 version of the medical insurance drug catalog, adding 74 drugs to the country All are included in the city's medical insurance drug catalog
.
Among these 74 new drugs, oncology drugs have attracted much attention
.
The rare disease drug that used to be 700,000 yuan per injection-Noxinagen Sodium Injection is also among them
.
The product was developed by Bojian and was launched in China on April 28, 2019.
It is used for the treatment of spinal muscular atrophy (SMA).
The initial domestic price was 699,700 yuan per tube
.
This year, the drug has dropped to 550,000 yuan.
After a new round of bargaining through national medical insurance negotiations, it is expected to drop to 33,000 yuan per injection in 2022
.
In addition to Nosinassen Sodium Injection, Ensatinib, Vometinib and Dacomitinib are used for the treatment of lung cancer, Donafenib is used for the treatment of liver cancer, Vedicutumab is used for the treatment of gastric cancer, and the treatment of breast cancer.
Blockbuster drugs such as Abexicil and Nirapali for the treatment of ovarian cancer have also been successfully included in the new drug list of medical insurance, which will bring the gospel of price reduction for the majority of cancer patients
.
It is worth mentioning that, in addition to including 74 new drugs in medical insurance, the Beijing Medical Insurance Bureau has also adjusted and improved some of the local drug reimbursement policies with higher annual costs, aiming to further reduce the burden on patients
.
For example, "fampridine sustained-release tablets" are included in the "multiple sclerosis" outpatient special disease drug reimbursement scope; 21 other new drugs including "Pamipalit capsules" are included in the outpatient clinics for malignant tumors and severe mental illness in Beijing Special disease medicine reimbursement scope
.
It is understood that "Pamipali Capsule" is mainly used to treat malignant tumors such as ovarian cancer and fallopian tube cancer.
The average annual drug cost of patients was about 250,000 yuan.
After national negotiations, the average annual drug cost has been reduced by more than half
.
It is reported that after the implementation of the reimbursement policy for special diseases in outpatient clinics in Beijing, the average annual cost of using the drug for retired employees will be further reduced to about 18,000 yuan, and the price reduction will be greatly increased
.
In addition, for drugs successfully negotiated by the country, for long-term outpatient treatment, high cost, and suitable for the treatment of various diseases, Beijing will refer to the reimbursement level of special disease drugs for urban employees and urban and rural residents in medical insurance outpatient clinics.
"Concentrated solution" and other 14 drugs will continue to be borne by the outpatient service at a fixed proportion and paid separately.
The basic medical insurance fund for urban employees is paid at 80%, and the basic medical insurance fund for urban and rural residents is paid at 70%; for metoprolol oral regular-release dosage forms The reimbursement scope of 513 drugs including omeprazole injection, and the reimbursement categories of 1263 drugs including clotrimazole oral regular-release dosage forms are also adjusted in accordance with national requirements
.
In general, starting from January 1 next year, a large number of patients in Beijing will enjoy the benefits of reduced-price drugs, reducing the burden of drug costs, increasing the availability of drugs, and improving the quality of life
.
.
The notice shows that from January 1, 2022, 74 new drugs will be added to the list of Beijing’s medical insurance drugs, a drop of more than half.
Beijing’s urban employees, urban and rural residents and other insured persons can enjoy reduced prices
.
It is reported that the notice is based on the adjustment of the national 2021 version of the drug catalog, the Beijing medical insurance drug catalog has been adjusted in and out, the scope and category of reimbursement for some drugs have been adjusted, and the reimbursement policy for medicines such as special diseases in outpatient clinics of this city has been adjusted.
Perfect
.
The 74 new drugs have an average decrease of 61.
71%, covering tumors, chronic diseases, anti-infection, rare diseases and other fields.
They are the nationally negotiated drugs for 2021.
The adjustment in Beijing is to implement the national 2021 version of the medical insurance drug catalog, adding 74 drugs to the country All are included in the city's medical insurance drug catalog
.
Among these 74 new drugs, oncology drugs have attracted much attention
.
The rare disease drug that used to be 700,000 yuan per injection-Noxinagen Sodium Injection is also among them
.
The product was developed by Bojian and was launched in China on April 28, 2019.
It is used for the treatment of spinal muscular atrophy (SMA).
The initial domestic price was 699,700 yuan per tube
.
This year, the drug has dropped to 550,000 yuan.
After a new round of bargaining through national medical insurance negotiations, it is expected to drop to 33,000 yuan per injection in 2022
.
In addition to Nosinassen Sodium Injection, Ensatinib, Vometinib and Dacomitinib are used for the treatment of lung cancer, Donafenib is used for the treatment of liver cancer, Vedicutumab is used for the treatment of gastric cancer, and the treatment of breast cancer.
Blockbuster drugs such as Abexicil and Nirapali for the treatment of ovarian cancer have also been successfully included in the new drug list of medical insurance, which will bring the gospel of price reduction for the majority of cancer patients
.
It is worth mentioning that, in addition to including 74 new drugs in medical insurance, the Beijing Medical Insurance Bureau has also adjusted and improved some of the local drug reimbursement policies with higher annual costs, aiming to further reduce the burden on patients
.
For example, "fampridine sustained-release tablets" are included in the "multiple sclerosis" outpatient special disease drug reimbursement scope; 21 other new drugs including "Pamipalit capsules" are included in the outpatient clinics for malignant tumors and severe mental illness in Beijing Special disease medicine reimbursement scope
.
It is understood that "Pamipali Capsule" is mainly used to treat malignant tumors such as ovarian cancer and fallopian tube cancer.
The average annual drug cost of patients was about 250,000 yuan.
After national negotiations, the average annual drug cost has been reduced by more than half
.
It is reported that after the implementation of the reimbursement policy for special diseases in outpatient clinics in Beijing, the average annual cost of using the drug for retired employees will be further reduced to about 18,000 yuan, and the price reduction will be greatly increased
.
In addition, for drugs successfully negotiated by the country, for long-term outpatient treatment, high cost, and suitable for the treatment of various diseases, Beijing will refer to the reimbursement level of special disease drugs for urban employees and urban and rural residents in medical insurance outpatient clinics.
"Concentrated solution" and other 14 drugs will continue to be borne by the outpatient service at a fixed proportion and paid separately.
The basic medical insurance fund for urban employees is paid at 80%, and the basic medical insurance fund for urban and rural residents is paid at 70%; for metoprolol oral regular-release dosage forms The reimbursement scope of 513 drugs including omeprazole injection, and the reimbursement categories of 1263 drugs including clotrimazole oral regular-release dosage forms are also adjusted in accordance with national requirements
.
In general, starting from January 1 next year, a large number of patients in Beijing will enjoy the benefits of reduced-price drugs, reducing the burden of drug costs, increasing the availability of drugs, and improving the quality of life
.
